Education
Osgoode Hall Law School (2016) JD
University of Toronto (2013) PhD (Chemistry)
Memorial University of Newfoundland (2008) BSc (Chemistry)

Bar Admissions
Ontario (2017)

Practice Areas
Intellectual Property

Contact
T 416-849-4564
cmcclary@litigate.com

Corey McClary

COREY MCCLARY
is counsel at Lenczner Slaght.

Corey's practice is primarily focused on intellectual property law, with an emphasis on pharmaceutical patent litigation. Corey has experience advising clients on complex disputes, including actions under the *Patented Medicines (Notice of Compliance) Regulations*, patent infringement and impeachment actions, and judicial review proceedings. Corey also regularly provides strategic patent and regulatory advice.

Prior to joining Lenczner Slaght, Corey summered, articled and practiced in the intellectual property litigation group at a leading international law firm in Toronto.

Before attending law school, Corey obtained a Ph.D. in organic chemistry. His graduate research focused on developing methods for the regioselective functionalization of carbohydrates and measuring the strength of non-covalent interactions. His research has been published in peer-reviewed scientific journals.

RECOGNITION

- Best Lawyers in Canada: Ones to Watch (2025-2027)
  Intellectual Property
- LMG Life Sciences Awards (2026)
  Rising Star – Canada

SELECT CASES

- **Genentech Inc and Hoffmann-La Roche Limited v Biosimilar Collaborations Ireland Limited –** Counsel to Genentech Inc and Hoffmann-La Roche Limited in a PM(NOC) action in the Federal Court in respect of Canadian Patent Nos. 2,788,253 and 2,711,798.
- **Hoffmann-La Roche Limited v The Minister of Health, Attorney General of Canada and Biosimilar Collaborations Ireland Limited –** Counsel to Hoffmann-La Roche Limited in an application for judicial review in the Federal Court, in respect of a decision made by the Minister of Health and its continued course of conduct in respect of the filing of a new drug submission by Biosimilar Collaborations Ireland Limited.
- **The NOCO Company, Inc. v Canadian Tire Corporation, Limited –** Counsel to Canadian Tire Corporation, Limited in an action for patent infringement in the Federal Court in respect of Canadian Patent No. 2,916,782.
- **Merck Canada Inc v The Minister of Health –** Counsel to Merck Canada Inc. in a judicial review proceeding in the Federal Court

regarding an application for a certificate of supplementary protection for Canadian Patent No. 2,670,892 and BELSOMRA.

- **Gilead Sciences, Inc et al v Pharmascience Inc –** Counsel to Gilead Sciences, Inc. and Gilead Sciences Canada, Inc. in a NOC action in the Federal Court in respect of Canadian Patent Nos. 2,845,553 and 2,990,210.
- **Bernard Charles Sherman v Pfizer Canada Inc –** Counsel to Pfizer Canada Inc. and Pfizer Inc. in an action for patent infringement in the Federal Court in respect of Canadian Patent No. 2,355,347.
- **Akebia Therapeutics Inc v Fibrogen Inc –** Counsel to FibroGen Inc. and AstraZeneca AB in an impeachment action in the Federal Court in respect of Canadian Patent Nos. 2,468,083, 2,467,689, and 2,526,496.
- **Gilead Sciences, Inc et al v JAMP Pharma Corporation –** Counsel to Gilead Sciences, Inc. and Gilead Sciences Canada, Inc. in a NOC action in the Federal Court in respect of Canadian Patent No. 2,990,210.
- **Gilead Sciences, Inc et al v Natco Pharma (Canada) Inc –** Counsel to Gilead Sciences, Inc. and Gilead Sciences Canada, Inc. in a NOC action in the Federal Court in respect of Canadian Patent No. 2,845,553.
- **Merck Canada Inc v The Minister of Health –** Counsel to Merck Canada Inc. in a judicial review proceeding in the Federal Court in regards to a patent listing for KEYTRUDA.
- **Gilead Sciences Inc, et al v JAMP Pharma Corporation –** Counsel to Gilead Sciences, Inc. and Gilead Sciences Canada, Inc. in a NOC action in the Federal Court in respect of Canadian Patent No. 2,845,553.
- **Genentech Inc. et al v Amgen Canada Inc. –** Counsel to Hoffmann-La Roche Limited and Genentech, Inc. in various Federal Court actions under the *PMNOC Regulations* in respect of trastuzumab (HERCEPTIN), which were the first actions under the new regime.
- **Novo Nordisk A/S et al v Teva Canada Limited –** Counsel to Novo Nordisk A/S and Novo Nordisk Canada Inc. in Federal Court actions under the *PMNOC Regulations* in respect of liraglutide (VICTOZA).
- **Gilead Sciences, Inc et al v Apotex Inc –** Counsel to Gilead Sciences, Inc. and Gilead Sciences Canada, Inc. in a NOC action in the Federal Court in respect of Canadian Patent Nos. 2,845,553 and 2,990,210.
- **Gilead Sciences, Inc et al v Natco Pharma (Canada) Inc –** Counsel to Gilead Sciences, Inc. and Gilead Sciences Canada, Inc. in a NOC action in the Federal Court in respect of Canadian Patent Nos. 2,845,553 and 2,990,210.
- **Gilead Sciences, Inc et al v Apotex Inc –** Counsel to Gilead Sciences, Inc. and Gilead Sciences Canada, Inc. in a NOC action in the Federal Court in respect of Canadian Patent No. 2,845,553.
- **Genentech Inc v Celltrion Healthcare Co –** Counsel to Hoffmann-La Roche Limited and Genentech, Inc. in various Federal Court actions under the new *PMNOC Regulations* in respect of trastuzumab (HERCEPTIN), which were the first actions under the new regime.

SELECT PUBLICATIONS AND PRESENTATIONS

- **The 18th Annual Harold G. Fox IP Moot –** Sana Halwani and Corey McClary served as judges at the annual Harold G. Fox IP Moot.
- **2025 Snapshot: Through the Lens of Lenczner Slaght –** We've released our *2025 Snapshot*, highlighting the most significant developments, decisions, and trends in litigation from the past year across 21 practice areas. Reflect on 2025 and look ahead to 2026

through the lens of our expert litigators.

- **Organoboron-Promoted Regioselective Glycosylations in the Synthesis of a Saponin-Derived Pentasaccharide from Spergularia ramosa –** Corey McClary co-authored the article *Organoboron-Promoted Regioselective Glycosylations in the Synthesis of a Saponin-Derived Pentasaccharide from Spergularia ramosa,* published in The Journal of Organic Chemistry.
- **Applications of Organoboron Compounds in Carbohydrate Chemistry and Glycobiology: Analysis, Separation, Protection and Activation –** Corey McClary co-authored the article *Applications of Organoboron Compounds in Carbohydrate Chemistry and Glycobiology: Analysis, Separation, Protection and Activation,* published in Carbohydrate Research.
- **Anion Receptors Composed of Hydrogen- and Halogen-Bond Donor Groups: Modulating Selectivity With Combinations of Distinct Noncovalent Interactions –** Corey McClary co-authored the article *Anion Receptors Composed of Hydrogen- and Halogen-Bond Donor Groups: Modulating Selectivity With Combinations of Distinct Noncovalent Interactions*, published in the Journal of the American Chemical Society.
- **Ligand Directed Self-Assembly vs. Metal Ion Coordination Algorithm - When Does the Ligand or the Metal Take Control? –** Corey McClary co-authored the article *Ligand Directed Self-Assembly vs. Metal Ion Coordination Algorithm - When Does the Ligand or the Metal Take Control?*, published in Dalton Transactions.

BLOG POSTS

- **Health Canada's Ministerial Reliance Order: A New Era in Canadian Drug Regulation –** Health Canada has introduced a new Ministerial Reliance Order (MRO) that represents a significant development in Canada's drug regulatory framework. The MRO creates a new mechanism allowing Health Canada, in defined circumstances, to rely on decisions or documents produced by comparable foreign regulatory authorities (FRAs) when reviewing certain drug submissions. The initiative aims to improve the efficiency of regulatory review while maintaining Canada's standards for safety, efficacy, and quality.
- **A Tale of Two Standards: Why Hikma May Have Had a Different Fate in Canada –** On June 4, 2026, the US Supreme Court issued its decision in *Hikma Pharmaceuticals USA Inc v Amarin Pharma Inc*, a motion to dismiss against the backdrop of a claim for inducement of patent infringement in the pharmaceutical context. The Court held that the patentee, Amarin, had not pleaded more than a "sheer possibility" that Hikma actively induced infringement under the applicable US plausibility standard. Would a Canadian court have reached the same conclusion on identical facts? Possible, but not "plausible."
- **Fall Regulatory Round Up – The Shifting Shape of the Canadian Landscape – Fall Regulatory Round Up**

  Activity abounds on the regulatory landscape from modernization and transparency initiatives to consultations, collaborations, and even potential implementations. Our Fall Regulatory Round Up highlights significant developments for drug products and patents that are of interest to those in the life sciences and biotech spaces. We will be following these important regulatory initiatives as they continue to unfold and will provide updates of interest.

SELECT NEWS ARTICLES

- **Corey McClary Named LMG Life Sciences Rising Star –** We are proud to announce that Corey McClary has been recognized as a Rising Star at the 2026 Life Sciences Americas Awards.
- **49 Lenczner Slaght Litigators Named in Best Lawyers in Canada 2027 –** In the 2027 edition of *Best Lawyers in Canada*, 49 of our expert litigators earned 172 rankings across 26 practice areas, a testament to the depth and breadth of our advocacy.
- **Lenczner Slaght Litigators Featured Among Best Lawyers in Canada –** The 2026 edition of *Best Lawyers in Canada* recognizes Lenczner Slaght with 180+ rankings, featuring 48 of our expert litigators across 27 practice areas.
- **Lenczner Slaght Litigators Recognized as the Best Lawyers in Canada –** In the 2025 edition of *Best Lawyers in Canada*, Lenczner Slaght is proud to receive 168 total rankings, with 45 of our expert litigators recognized for their expertise across 25 practice areas.
- **Corey McClary Joins Lenczner Slaght's IP Team –** Canada's leading litigation firm continues to grow its expert Intellectual Property Group with the addition of another exceptional lawyer, Corey McClary.

PROFESSIONAL ACTIVITIES

- Toronto Intellectual Property Group
- Ontario Bar Association
- Intellectual Property Institute of Canada
  Patent Committee (2025-2027)